The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Clinical Roundup

ColoAlert test identifies novel mRNA biomarkers in colorectal cancer, study shows

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

The ColoFuture study, a multi-center international clinical trial assessing the potential to integrate a portfolio of novel mRNA biomarkers into ColoAlert, has demonstrated positive topline results. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Guest Editorial

Regulation must keep up with scientific advances

The American Cancer Society’s recent report on the increasing incidence rates of colorectal cancer in young adults once again rang an alarm bell for adults over 45 to get checked, especially if they are having symptoms. But as an oncologist with more than 40 years of experience, I also believe that this should be a clarion call to scientists and researchers, and for regulators at the FDA.
By Richard M. Goldberg
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account